Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery

被引：0
|
作者：
Bradley-Kennedy, C. [1 ]
Wolowacz, S. E. [2 ]
Roskell, N. S. [3 ]
Plumb, J. M. [4 ]
机构：
[1] Boehringer Ingelheim Ltd, Hlth Econ & Outcomes Res, Burlington, ON, Canada
[2] RTI Hlth Solut Ltd, Hlth Econ, Manchester, England
[3] RTI Hlth Solut Ltd, Biometr, Manchester, England
[4] Boehringer Ingelheim GmbH & Co KG, Hlth Econ & Outcomes Res, Ingelheim, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-470
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR TOTAL KNEE REPLACEMENT SURGERY
    Wolowacz, S.
    Roskell, N.
    Maciver, F.
    Beard, S.
    Robinson, P.
    Plumb, J.
    VALUE IN HEALTH, 2008, 11 (06) : A404 - A404
  • [2] Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery (TKR)
    Bradley-Kennedy, C.
    Wolowacz, S. E.
    Roskell, N. S.
    Plumb, J. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 786 - 786
  • [3] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN TOTAL HIP AND KNEE REPLACEMENT IN PORTUGAL
    Mateus, C.
    Wolowacz, S.
    Pereira, J. A.
    VALUE IN HEALTH, 2009, 12 (03) : A148 - A148
  • [4] Cost-effectiveness of dabigatran etexilate 150 mg in Canada for the prevention of venous thromboembolism in patients undergoing total knee or hip arthroplasty that have moderate impairment of renal function
    Bradley-Kennedy, C.
    Wolowacz, S. E.
    Roskell, N. S.
    Clemens, A.
    Plumb, J. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 785 - 786
  • [5] Dabigatran etexilate and LMWH for the prevention of venous thromboembolism in 532 patients undergoing hip surgery
    Bonarelli, S.
    Bacchin, M. R.
    Frugiuele, I.
    Feoli, M. A.
    Facchini, F.
    Altimari, V.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (05) : 897 - 903
  • [6] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS AGED OVER 75 YEARS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY
    Wolowacz, S.
    Roskell, N.
    Plumb, J.
    Clemens, A.
    Robinson, P.
    Dolan, G.
    Brenkel, I
    VALUE IN HEALTH, 2009, 12 (03) : A151 - A151
  • [7] Economic Evaluation of Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Total Knee and Hip Replacement Surgery
    Wolowacz, Sorrel E.
    Roskell, Neil S.
    Maciver, Fiona
    Beard, Stephen M.
    Robinson, Paul A.
    Plumb, Jonathan M.
    Dolan, Gerry
    Brenkel, Ivan J.
    CLINICAL THERAPEUTICS, 2009, 31 (01) : 194 - 212
  • [8] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, E.
    VALUE IN HEALTH, 2011, 14 (03) : A40 - A40
  • [9] ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN
    Gonzalez-Rojas, N.
    Vieta, A.
    Monreal, M.
    Wolowacz, S. E.
    VALUE IN HEALTH, 2009, 12 (07) : A440 - A440
  • [10] Dabigatran Etexilate A Review of its Use for the Prevention of Venous Thromboembolism after Total Hip or Knee Replacement Surgery
    Burness, Celeste B.
    McKeage, Kate
    DRUGS, 2012, 72 (07) : 963 - 986
12345